Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Pracinostat (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 27 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2017 Planned End Date changed from 1 Jan 2018 to 12 Jan 2019.
- 24 Jan 2017 Planned primary completion date changed from 1 Jan 2018 to 12 Jan 2019.